TY - JOUR
T1 - Effect of a 5-HT1A receptor agonist, flesinoxan, on the extracellular noradrenaline level in the hippocampus and on the locomotor activity of rats
AU - Suwabe, Akira
AU - Kubota, Masaharu
AU - Niwa, Masanobu
AU - Kobayashi, Kazuhiko
AU - Kanba, Shigenobu
N1 - Funding Information:
The authors thank Dr. Michio Nakagawara (Yokosuka Kyousai Hospital) and Emeritus Professor Tetsuhiko Kariya (Yamanashi Medical University) for helpful advice, Dr. Yoshimitsu Hiejima (Department of Mathematical Informative Science, Yamanashi Medical University) for helpful advice on statistical analysis. The authors also thank the Solvay Seiyaku and Wyeth-Ayerst Research for their donation of flesinoxan and WAY100635, respectively. This research was in part supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture, the Ministry of Health and Welfare, and Ohme Keiyu Hospital.
PY - 2000/3/10
Y1 - 2000/3/10
N2 - We have studied effects of 5-hydroxytryptamine 1A (5-HT1A) receptor-selective compounds on the extracellular noradrenaline (NA) level in the hippocampus of rats using microdialysis and on their locomotor activity. A selective 5-HT1A) receptor agonist, flesinoxan (5 mg/kg, i.p.) increased the extracellular NA level in the hippocampus, and increased the locomotor activity. Both responses were blocked by pretreatment with a 5-HT1A receptor antagonist, WAY100635 (1 mg/kg, i.p.) and an α2 adrenoceptor agonist, clonidine (50 μg/kg, i.p.). Bilateral intrahippocampal injection of flesinoxan (200 nmol in 2 μl, respectively) increased the locomotor activity of rats and the intrahippocampal perfusion of flesinoxan (1 mM, 2 μl/min) increased the extracellular NA level in the hippocampus. Bilateral intrahippocampal injections of a small amount of WAY100635 (0.1 nmol in 2 μl, respectively) blocked the flesinoxan (5 mg/kg, i.p.)-induced hyperactivity. Flesinoxan (5 mg/kg, i.p.) did not significantly influence the level of serotonin or its major metabolite in the hippocampus, or dopamine or its metabolites in the striatum. In conclusion, these behavioral as well as pharmacological results indicate that postsynaptic 5-HT1A receptor activation by flesinoxan increase the extracellular NA level in the hippocampus, which may be the cause of the increase of the locomotor activity.
AB - We have studied effects of 5-hydroxytryptamine 1A (5-HT1A) receptor-selective compounds on the extracellular noradrenaline (NA) level in the hippocampus of rats using microdialysis and on their locomotor activity. A selective 5-HT1A) receptor agonist, flesinoxan (5 mg/kg, i.p.) increased the extracellular NA level in the hippocampus, and increased the locomotor activity. Both responses were blocked by pretreatment with a 5-HT1A receptor antagonist, WAY100635 (1 mg/kg, i.p.) and an α2 adrenoceptor agonist, clonidine (50 μg/kg, i.p.). Bilateral intrahippocampal injection of flesinoxan (200 nmol in 2 μl, respectively) increased the locomotor activity of rats and the intrahippocampal perfusion of flesinoxan (1 mM, 2 μl/min) increased the extracellular NA level in the hippocampus. Bilateral intrahippocampal injections of a small amount of WAY100635 (0.1 nmol in 2 μl, respectively) blocked the flesinoxan (5 mg/kg, i.p.)-induced hyperactivity. Flesinoxan (5 mg/kg, i.p.) did not significantly influence the level of serotonin or its major metabolite in the hippocampus, or dopamine or its metabolites in the striatum. In conclusion, these behavioral as well as pharmacological results indicate that postsynaptic 5-HT1A receptor activation by flesinoxan increase the extracellular NA level in the hippocampus, which may be the cause of the increase of the locomotor activity.
UR - http://www.scopus.com/inward/record.url?scp=0034628976&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034628976&partnerID=8YFLogxK
U2 - 10.1016/S0006-8993(00)01941-7
DO - 10.1016/S0006-8993(00)01941-7
M3 - Article
C2 - 10708692
AN - SCOPUS:0034628976
SN - 0006-8993
VL - 858
SP - 393
EP - 401
JO - Molecular Brain Research
JF - Molecular Brain Research
IS - 2
ER -